BCR and aneurysmal bone cyst: Thus, NIK appears to be an attractive new therapeutic target for ABC-DLBCL treatment, particularly for patients with ABC-DLBCL that are refractory to bortezomib or to the BCR pathway inhibitor ibrutinib.